Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
24 avr. 2023 07h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral...
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
10 avr. 2023 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
28 mars 2023 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
23 mars 2023 16h44 HE
|
Aptose Biosciences, Inc.
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML...
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
10 mars 2023 18h44 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
09 mars 2023 16h05 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
02 mars 2023 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
30 janv. 2023 07h00 HE
|
Aptose Biosciences, Inc.
• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for...
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
28 déc. 2022 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Establishes New At-The-Market Facility
12 déc. 2022 06h15 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...